Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BDA-366, a potent Bcl2 antagonist, selectively binds the Bcl2-BH4 domain with high affinity (Ki = 3.3 nM), inducing a conformational change that nullifies its antiapoptotic function, thereby transforming it into a pro-apoptotic entity. This compound effectively suppresses lung cancer cell growth[1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 78.00 | |
2 mg | In stock | $ 113.00 | |
5 mg | In stock | $ 183.00 | |
10 mg | In stock | $ 311.00 | |
25 mg | In stock | $ 523.00 | |
50 mg | In stock | $ 759.00 | |
100 mg | In stock | $ 1,060.00 |
Description | BDA-366, a potent Bcl2 antagonist, selectively binds the Bcl2-BH4 domain with high affinity (Ki = 3.3 nM), inducing a conformational change that nullifies its antiapoptotic function, thereby transforming it into a pro-apoptotic entity. This compound effectively suppresses lung cancer cell growth[1]. |
In vitro | NSC 228155 promotes transactivation of several RTKs, including ErbB2 and ErbB3, Insulin R and IGF-1 R receptors in the cells. It stimulates dimerization of sEGFR domain II[1]. NSC 228155 can rapidly move across cell membranes and disperse within both cytoplasmic and nuclear compartments. It rapidly generates hydrogen peroxide within cells[2]. NSC 228155 is also a potent inhibitor of KIX-KID interaction(IC50 = 0.36 μM), but it is not particularly selective against CREB-mediated gene transcription in HEK 293T cells[3]. |
Molecular Weight | 423.5 |
Formula | C24H29N3O4 |
CAS No. | 1909226-00-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 5 mg/mL (11.8 mM)
DMSO: 78 mg/mL (184.2 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BDA-366 1909226-00-1 Apoptosis BCL Inhibitor Antitumor Bcl-2 Family inhibit Bcl2-BH4 domain Anticancer BDA 366 Antiapoptotic function BDA366 Lung cancer inhibitor